TORONTO, July 15, 2008 (PRIME NEWSWIRE) -- Polydex Pharmaceuticals Limited (the "Company"), (Nasdaq:POLXF) announced today that on July 14, 2008, it received a Nasdaq Staff Determination Letter from The NASDAQ Stock Market stating that the Company had not regained compliance with the $1.00 minimum bid price requirement for continued listing as set forth in Marketplace Rule 4310(c)(4) during the preceding 180-day period as set forth in NASDAQ's letter of deficiency to the Company on January 16, 2008.
